Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses the 2018 significant NSCLC trials including EMPOWER, KEYNOTE-189, & MYSTIC. This year will be very significant for clarification of the landscaping front-line therapy on non-small-cell lung cancer (NSCLC) with a number of trials and studies being mentioned. It is highly anticipated to see final and definitive results about the combination of checkpoint inhibitors in the front-line and the combination of checkpoint inhibitors and chemotherapy in order to solidify the existing data of these combinations.
2018 Significant NSCLC Trials EMPOWER, KEYNOTE-189, & MYSTIC
